BiotechTube

SER-262 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile Infection

Conditions

Clostridium Difficile Infection

Trial Timeline

Aug 1, 2016 → Aug 1, 2018

NCT ID
NCT02830542

About SER-262 + Placebo

SER-262 + Placebo is a phase 1 stage product being developed by Seres Therapeutics for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02830542. Target conditions include Clostridium Difficile Infection.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02830542Phase 1Completed

Competing Products

20 competing products in Clostridium Difficile Infection

See all competitors
ProductCompanyStageHype Score
Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
85
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
23
OPT-80 + vancomycinAstellas PharmaPhase 3
77
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
77
Fidaxomicin + VancomycinAstellas PharmaApproved
85
Fidaxomicin + VancomycinMerckApproved
85
fidaxomicin + PlaceboMerckPhase 3
77
Surotomycin + PlaceboMerckPhase 1
33
CB-183,315 + Placebo + VancomycinMerckPhase 2
52
Surotomycin + PlaceboMerckPhase 1
33
MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
77
Vancomycin + FidaxomicinMerckApproved
85
FidaxomicinMerckPre-clinical
23
Bezlotoxumab + Standard CDI treatmentMerckPre-clinical
23
MK-3415 + MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
77
Fidaxomicin + Vancomycin + Matching Placebo to FidaxomicinMerckPhase 3
77
bezlotoxumab + Vancomycin OralMerckApproved
85
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)MerckPhase 3
77
Bezlotoxumab Injection [Zinplava]MerckPre-clinical
23
PAR-101/OPT-80 + VancomycinMerckPhase 3
77

Other Products from Seres Therapeutics

SER-109 + PlaceboPhase 3
69
SER-109Phase 3
69
SER-109 + PlaceboPhase 2
44
Vancomycin Pre-Treatment + Placebo for Vancomycin Pre-Treatment + SER-287 + Placebo for SER-287Phase 2
44
Placebo for antibiotic + Vancomycin pretreatment + Nivolumab + Matching Placebo for SER-401 + SER-401Phase 1
25